Jizong Zhao Selected Research

Moyamoya Disease (Moya-Moya Disease)

1/2021	MMP-9 as a Biomarker for Predicting Hemorrhagic Strokes in Moyamoya Disease.
7/2020	RNF213 gene polymorphism rs9916351 and rs8074015 significantly associated with moyamoya disease in Chinese population.
6/2020	Combined STA-MCA Bypass and Encephalodurosynangiosis Versus Encephalodurosynangiosis Alone in Adult Hemorrhagic Moyamoya Disease: A 5 -Year Outcome Study.
12/2019	Cranioplasty after decompressive craniectomy in hemorrhagic moyamoya disease.
11/2019	Clinical Features and Surgical Outcomes of Patients With Moyamoya Disease and the Homozygous RNF213 p.R4810K Variant.
4/2018	Encephaloduroateriosynangiosis versus conservative treatment for patients with moyamoya disease at late Suzuki stage.
3/2018	Risk Factors for Epilepsy Recurrence after Revascularization in Pediatric Patients with Moyamoya Disease.
10/2017	Altered expression of circular RNAs in Moyamoya disease.
9/2017	Steroid sulfatase and filaggrin mutations in a boy with severe ichthyosis, elevated serum IgE level and moyamoya syndrome.
7/2017	Long-Term Outcome After Conservative Treatment and Direct Bypass Surgery of Moyamoya Disease at Late Suzuki Stage.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jizong Zhao Research Topics

Disease

18	Moyamoya Disease (Moya-Moya Disease) 01/2021 - 02/2011
17	Glioma (Gliomas) 04/2022 - 07/2009
16	Intracranial Aneurysm (Cerebral Aneurysm) 01/2021 - 12/2002
15	Aneurysm (Aneurysms) 01/2021 - 12/2002
10	Neoplasms (Cancer) 04/2022 - 07/2009
8	Stroke (Strokes) 01/2022 - 07/2003
7	Glioblastoma (Glioblastoma Multiforme) 02/2021 - 06/2015
5	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 01/2021 - 11/2003
5	Arteriovenous Malformations (Arteriovenous Malformation) 01/2021 - 07/2012
4	Ischemic Stroke 11/2021 - 09/2003
4	Hemorrhagic Stroke 01/2021 - 07/2003
4	Rupture 01/2021 - 11/2011
4	Hemorrhage 01/2021 - 07/2012
3	Edema (Dropsy) 01/2020 - 08/2002
3	Inflammation (Inflammations) 07/2017 - 11/2011
3	Intracranial Vasospasm 01/2011 - 07/2004
2	Pathologic Constriction (Stenosis) 04/2022 - 06/2018
2	Ischemia 10/2021 - 07/2015
2	Brain Injuries (Brain Injury) 01/2021 - 01/2013
2	Ruptured Aneurysm 01/2021 - 01/2021
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 01/2020
2	Hypertension (High Blood Pressure) 01/2021 - 05/2020
2	Cerebral Hemorrhage 01/2020 - 09/2003
2	Hematoma 01/2020 - 01/2015
2	Carcinogenesis 06/2015 - 08/2013
2	Epilepsy (Aura) 07/2012 - 01/2011
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 04/2022
1	Consciousness Disorders 01/2022
1	Dementia (Dementias) 10/2021
1	Cognitive Dysfunction 10/2021
1	Brain Neoplasms (Brain Tumor) 01/2021
1	COVID-19 12/2020
1	Myxoma (Myxomas) 03/2020
1	Parkinson Disease (Parkinson's Disease) 01/2020
1	X-Linked Ichthyosis (Ichthyosis, X Linked) 09/2017
1	Ichthyosis Vulgaris (Dominant Ichthyosis Vulgaris) 09/2017
1	Atopic Dermatitis (Atopic Eczema) 09/2017
1	Ichthyosis (Xeroderma) 09/2017
1	Muscle Weakness 09/2017

Drug/Important Bio-Agent (IBA)

10	RNA (Ribonucleic Acid)IBA 04/2022 - 07/2009
8	Messenger RNA (mRNA)IBA 01/2021 - 12/2002
8	Proteins (Proteins, Gene)FDA Link 07/2020 - 07/2009
7	Long Noncoding RNAIBA 01/2020 - 09/2016
6	Biomarkers (Surrogate Marker)IBA 04/2022 - 05/2014
4	HomocysteineIBA 10/2021 - 09/2003
2	Indicators and Reagents (Reagents)IBA 10/2021 - 01/2016
2	Circular RNAIBA 01/2021 - 10/2017
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2016
2	Matrix Metalloproteinases (MMPs)IBA 01/2021 - 07/2012
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2021 - 05/2016
2	Immunoglobulin E (IgE)IBA 10/2020 - 09/2017
2	LigandsIBA 01/2020 - 06/2014
2	gamma-glutamylaminomethylsulfonic acid (GAMS)IBA 01/2020 - 01/2020
2	Temozolomide (Temodar)FDA LinkGeneric 01/2018 - 01/2016
2	Biological ProductsIBA 01/2018 - 11/2016
2	ResveratrolIBA 01/2016 - 06/2015
2	MicroRNAs (MicroRNA)IBA 01/2016 - 08/2013
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2014 - 08/2002
2	Cyclic AMP Response Element-Binding Protein (Cyclic AMP-Responsive DNA-Binding Protein)IBA 09/2012 - 01/2012
2	Cell Adhesion MoleculesIBA 11/2011 - 07/2009
2	fasudil (AT 877)IBA 01/2011 - 09/2006
2	Nimodipine (Modus)FDA LinkGeneric 01/2011 - 09/2006
2	Calcitonin Gene-Related PeptideIBA 01/2009 - 07/2004
2	Desflurane (I 653)FDA Link 01/2009 - 07/2004
1	Monomeric GTP-Binding ProteinsIBA 04/2022
1	poly-4-dioxan-2-oneIBA 04/2022
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022
1	6-methyladenineIBA 02/2021
1	Nicotine FDA Link 01/2021
1	Troponin IIBA 01/2021
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021
1	Atorvastatin (Lipitor)FDA Link 01/2021
1	N-acetyltalosaminuronic acid (NAT)IBA 12/2020
1	Nucleic AcidsIBA 12/2020
1	Antihypertensive Agents (Antihypertensives)IBA 05/2020
1	InterferonsIBA 01/2020
1	CXCR3 ReceptorsIBA 01/2020
1	AdiponectinIBA 01/2020
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2020
1	Interleukin-10 (Interleukin 10)IBA 01/2020
1	MucinsIBA 01/2020
1	Protons (Proton)IBA 01/2020
1	Hepatitis B Surface Antigens (HBsAg)FDA Link 05/2019
1	MAP-kinase-activated kinase 5IBA 01/2018
1	Filaggrin ProteinsIBA 09/2017
1	Steryl-Sulfatase (Steroid Sulfatase)IBA 09/2017

Therapy/Procedure

9	Therapeutics 11/2021 - 09/2003
8	Craniotomy 12/2020 - 07/2004
4	Conservative Treatment 03/2020 - 10/2015
3	Cerebral Revascularization 06/2020 - 02/2011
2	Secondary Prevention 07/2017 - 05/2016
2	Ligation 06/2017 - 03/2003
2	Anesthesia 01/2009 - 07/2004
1	Stents 04/2022
1	Spinal Cord Stimulation 01/2022
1	Transplantation 11/2021
1	Rejuvenation 10/2021
1	Endovascular Procedures 10/2020
1	Decompressive Craniectomy 12/2019
1	Operative Surgical Procedures 03/2018